BRAF and thyroid cancer: This is observed in patients with iodine refractory thyroid cancer, with poorly differentiated, Hürthle cell cancer, PTC with aggressive features (tall cell variant) or with the BRAF V600E mutation and less frequently in patients with well differentiated papillary or follicular carcinoma.